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Background: MicroRNAs (miRNAs) are small, non-coding RNAs that can function as oncogenes or tumor
suppressors in human cancer. Abnormally expressed miR-224 was found to play a fundamental role in several types
of cancer. The aim of this study was to investigate the prognostic and biological values of miR-224 in colorectal
cancer (CRC).
Methods: Quantitative RT-PCR (qRT-PCR) was used to evaluate expression levels of miR-224. The postoperative
survival rate was analyzed with Kaplan–Meier method. The roles of miR-224 in cell proliferation, migration and
invasion were analyzed with pre-miR-224 transfected cells. In addition, the regulation of SMAD4 by miR-224 was
evaluated by qRT-PCR, Western blotting and luciferase reporter assays.
Results: In the present study, we demonstrated that miR-224 was significantly up-regulated in CRC tissue samples
and associated with disease relapse and a relative poorer disease-free survival rate. Moreover, ectopic expression of
miR-224 potently promoted tumor cell proliferation, migration and invasion in vitro. Furthermore, the over-
expression of miR-224 in CRC cell lines decreased SMAD4 expression at the translational level and decreased
SMAD4-driven luciferase-reporter activity.
Conclusions: Our data suggest that miR-224 could play an oncogenic role in the cellular processes of CRC and
represent a novel biomarker for tumor relapse of CRC patients.
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Colorectal carcinoma (CRC) is one of the most common
cancers, and is a significant contributor to cancer death
[1]. Although surgery currently offers the possibility of
prolonged survival for CRC patients, a significant num-
ber of patients with CRC who undergo curative surgery
develop local recurrence or distant metastasis, leading to
shorter survival [2]. A better understanding of the mo-
lecular mechanisms underlying tumor recurrence or me-
tastasis is essential to facilitate the prevention and
treatment of advanced CRC.* Correspondence: zhoutong0088@163.com
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reproduction in any medium, provided the orMicroRNAs (miRNAs) are endogenous non-coding
RNAs that negatively regulate target gene expressions by
binding to 3′-untranslated region (UTR) [3,4]. MiRNAs
participate in gene regulation, apoptosis, hematopoietic
development, the maintenance of cell differentiation,
and tumor genesis [5,6]. The dysregulation of miRNAs is
common in various carcinomas and plays an important
role in tumorigenesis, tumor progression, metastasis and
relapse in cancers [7-9].
Recently, miR-224 has been shown to be up-regulated
in cervical cancer and pancreatic ductal adenocarcin-
omas [10,11], and the involvement of miR-224 in the
tumorigenesis and development of breast cancer and he-
patocellular carcinoma has also been reported [12,13].
Previous reports revealed that miR-224 was upregulated
in CRC by miRNA microarray analysis [14,15]. More-
over, miR-224 is one of the most highly differentiallyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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over-expression induces the resistant phenotype in HT29
colon cancer cells [16]. Taken together, these studies sug-
gest that miR-224 functions as an oncogenic miRNA. How-
ever, the association between miR-224 and relapse of
colorectal cancer has not been evaluated yet, and the bio-
logical roles of miR-224 in CRC remain poorly understood.
Thus, we investigated the relationship between expres-
sion level of miR-224 and prognosis in CRC, and further
studied the possible function of miR-224 in the CRC cell
line. Our study results showed the high expression level
of miR-244 in CRC was significantly associated with a
relative poorer disease-free survival rate. Moreover, we
also demonstrated miR-224 promoted proliferation, mi-
gration and invasion of SW480 cells, at least partially
through suppression of SMAD4 expression.
Materials and methods
Patients and tissue samples
A total of 108 stage I-II (UICC, 6th ed., 2002) colorectal
patients received radical surgery at the First Department of
General Surgery, the Affiliated Hospital of North Sichuan
Medical College, from January 2004 to January 2009, were
collected. All clinicopathological characteristics of patients
with disease relapse (n=40) or without disease relapse
(n=68) within 3 years after surgery were available for all pa-
tients. Disease relapse was defined as local recurrence or
distant metastasis of colorectal cancer. All tissue specimens
were derived from 108 patients who did not received neo-
adjuvant therapy before surgery. The patients who received
postoperative adjuvant therapy were also excluded. To test
whether miR-224 was differentially expressed between
paired tumor and adjacent normal tissue in the same sub-
ject, we recruited a second cohort comprising 20 CRC pa-
tients. All tissue samples were immediately frozen in liquid
nitrogen and stored at −80°C for subsequent analysis. The
median follow-up time was 48.3 months (12.6–62.5
months) until June, 2012. Disease-free survival (DFS) was
calculated from radical surgery to the first disease relapse.
Informed written consent was obtained from each patient,
and research protocols were approved by the Medical
Ethics Committee of North Sichuan Medical College.
Cell culture
The human CRC cell line SW480 was purchase from
American Type Culture Collection. The cells were main-
tained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 100 u/ml penicillin
and 100 mg/ml streptomycin, at 37°C in a humidified
atmosphere of 5% CO2.
RNA extraction and real-time RT–PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA). The PCR primers for miR-224and U6 were purchased from Applied Biosystems (Ap-
plied Biosystems, Foster City, CA, USA). The PCR
primers for SMAD4 were 5′-TGGCCCAGGATC AGT
AGGT-3′ and 5′-CATCAACACCAATTCCAGCA-3′.
The primers for β-actin: 5′-CCAAGGCCAACCGCGA
GAAGATGAC-3′ and 5′-AGGGTACAT GGTGGTGC
CGCCAGAC-3′. The first-strand cDNA was synthesized
using the PrimeScript RT reagent Kit (TaKaRa, Dalian,
China). Real-time PCR was performed using SYBR Pre-
mix Ex Taq (TaKaRa) and measured in a LightCycler
480 system (Roche, Basel, Switzerland). U6 or β-actin
was used as internal control. Relative gene expression
was calculated using 2-ΔCT method, and fold change of
gene was calculated using the equation 2-ΔΔCT.
Transfection of miRNA
Ectopic expression of miR-244 in cells was achieved by
transfection with Pre-miR-224 precursor (pre-miR-224)
(Ambion, Foster City, CA, USA) using Lipofectamine 2000
(Invitrogen). 2 ×105 cells were seeded into each well of a
6-well plate and transfected for 24 h or 48 h. Transfected
cells were used in further assays or RNA/protein extraction.
MTT assay
2×104 SW480 cells were plated onto 96-well plates for
24 h. The cells were then transfected with 50 nM pre-
miR-224 or pre-miR-nc. At different time points (24 h,
48 h and 72 h), the culture medium was removed and
replaced with culture medium containing 10μl of sterile
MTT dye (5 mg/ml). After incubation at 37°C for 4 h,
the MTT solution was removed, and 150μl dimethyl
sulfoxide (DMSO) was added to each well followed by
measuring the absorbance at 570 nm on an enzyme im-
munoassay analyzer (Bio-Rad).
Migration and invasion assays
For migration assays, 5×104 cells transfected with either pre-
miR-224 or pre-miR-nc were placed into Boyden chambers
(Corning, Cambridge, MA, USA) with an 8.0mm pore
membrane. For invasion assays, 5×104 cells were placed into
chambers coated with 150μg of Matrigel (BD Biosciences,
Bedford, MD, USA). Medium containing 10% fetal bovine
serum in the lower chamber served as the chemoattractant.
After the cells were incubated for 48 h at 37°C in a humidi-
fied incubator with 5% CO2, the cells remaining on the
upper surface of the membranes were removed, whereas the
cells adhering to the lower surface were fixed, stained with
hematoxylin and counted under a microscope at a magnifi-
cation of 400× to calculate their relative numbers.
Western blot analysis
Immunoblotting was performed to detect the expression
of SMAD4 in CRC cell lines. Transfected cells were
lysed in RIPA lysis buffer (ProMab Biotechnology). Protein
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onto PVDF membrane. After probed with 1:500 diluted
mouse polyclonal SMAD4 antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) at 4°C overnight, the blots
were subsequently incubated with HRP-conjugated sec-
ondary antibody (1:5000). Signals were visualized using
ECL Substrates (Millipore, MA, USA). GAPDH was used
as an endogenous protein for normalization.
Luciferase assay
For luciferase reporter experiments, the wild-type and
mutated 3′UTR of SMAD4 mRNA were subcloned into
the XhoI and NotI site of the psicheck-2 vector (Promega)
and the new vectors were named psicheck-2-SMAD4-WT
and psicheck-2-SMAD4-MUT, respectively. The primers
as shown in Table 1 were used to amplify specific
fragments. For reporter assay, HEK 293T cells were plated
onto 24-well plates at 2×104 cells/well and transfected
with 200 ng of psicheck-2-SMAD4-WT or psicheck-
2-SMAD4-MUT and 40 nM pre-miR-224 or pre-miR-nc
using Lipofectamine 2000 (Invitrogen). Firefly luciferase
was used to normalize the Renilla luciferase. After trans-
fection for 48h, cells were harvested and assayed with
Dual-Luciferase Reporter Assay System (Promega) accord-
ing to the manufacturer’s protocols.
Statistical analysis
All data presented in this study have been repeated at
least three times from three independent experiments.Table 1 PCR primers and oligonucleotide sequences of
constructs in luciferase reporter assay
Targets Type Primers Oligonucleotide sequence (5′-3′)
SMAD4
















SMAD MUT3 Sense GATTAACACTGAATGGCTGGATCATT
CAGAGCTCTCTTCT
(site3) Antisense GCCATTCAGTGTTAATCAAAATGGAC
CTAAAAAGAGCCAContinuous variables were expressed as the mean ±
standard deviation. Measurement data were analyzed
using Student's t-test, while categorical data were stud-
ied using chi-square test. Receiver operating characteris-
tic (ROC) curve was used to determine the cut off value
of miR-224 expression. The postoperative survival rate
was analyzed with Kaplan–Meier method, and differ-
ences in survival rates were assessed with log-rank test.
All statistical analyses were performed using SPSS 16.0
software (SPSS, Chicago, IL, USA). Two-sided P-values
were calculated, and differences were considered signifi-
cant at P-values of <0.05.
Results
Patients’ characteristics
A total of 108 patients were included in this study with
40 patients in relapse group (relapse within 3 years after
radical surgery) and 68 patients in non-relapse group
(no relapse within 3 years after radical surgery). There
were no differences between the two groups in terms of
age, gender, tumor location, differentiation and TNM
stage. The details were seen in Table 2.
Correlations between miR-224 expressions and disease
relapse
In this study, we found that miR-224 expression in
tumor tissues was significantly higher than that in nor-
mal tissues (P<0.01, Figure 1A). Using the samples from
the second cohort, we found that the miR-224 expres-
sion levels were significantly up-regulated in the tissues
of CRC patients with disease relapse (n=40) compared
with those without disease relapse (n=68) (P<0.01,Table 2 Clinicopathological characteristics of colorectal
cancer patients
Relapse (n=40) Nonrelapse (n=68) p-Value
Age (years) 66(35–82) 66(31–81) 0.576
Gender






Well, moderate 22 44




Well: well-differentiated adenocarcinoma,moderate: moderately differentiated
adenocarcinoma, poor: poorly differentiated adenocarcinoma, mucinous:
mucinous carcinoma.
Relapse non-relapse   p-Value
miR-224 High     27         21      <0.001**




Figure 1 miR-224 is up-regulated in CRC tissues and associated with the relapse of CRC. (A) The expression of miR-224 in CRC tumor tissues
was significantly higher than in their paired normal colorectal tissues. (B) The average expression level of miR-224 was higher in relapse group (n=40)
than that in non-relapse group (n=68). (C) Chi-square test and Kaplan-Meier analysis were used to demonstrate that high expression of miR-224 was
significantly associated with disease relapse (P<0.001) and a relative poorer disease-free survival rate (P=0.001). **P<0.01.
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categorized as low or high in relation to the cutoff value
(25.72) on the basis of ROC curve analysis. Therefore,
48 patients were included in the high expression group
and 60 in the low-expression group. Among patients
with miR-224 high expression, 27 patients relapsed (27/48,
56.3%), while only 13 patients relapsed (13/60, 21.7%)
among patients with miR-224 low expression. Using
chi-square test and Kaplan-Meier analysis, the results
demonstrated that high miR-224 expression was signifi-
cantly associated with disease relapse and a relative poorer
disease-free survival rate (Figure 1B).
MiR-224 promotes CRC cell proliferation
MiR-224 was upregulated in CRC, implicating its poten-
tial role in CRC cells biological properties. To further
characterize the functional importance in CRC tumori-
genesis, we examined the effect of miR-224 on the pro-
liferation of CRC cells using MTT assay. Compared to
pre-miR-nc, transfection with pre-miR-224 in SW480
cells led to an approximately 6-fold increase in miR-224
expression as detected by qRT-PCR (Figure 2A). We ob-
served that overexpression of miR-224 significantly pro-
moted the proliferation of SW480 cells, at 24, 48, 72 h
after transfection (P<0.05, Figure 2B).
MiR-224 regulates CRC cell invasion and migration in vitro
The potential roles of miR-224 in CRC cell migration and
invasion were assessed using transwell migration and inva-
sion assays. We observed that cell migration was signifi-
cantly increased following transfection with pre-miR-224
compared with the negative control (P<0.01, Figure 3A,
3B). We then examined the effect of miR-224 on cell inva-
sion across an extracellular matrix and showed that in
SW480 cells, the overexpression of miR-224 markedlyFigure 2 MiR-224 promotes CRC cell proliferation. (A) miR-224 express
assay was performed to determine SW480 proliferation. *P<0.05. **P<0.01.enhanced the invasive potential compared with the control
(P<0.05, Figure 3A, 3B). These observations suggest that
miR-224 plays an important role in promoting migration
and invasive ability of CRC cells.
MiR-224 binds to the 3′UTR of SMAD4
Analysis by using publicly available programs, TargetScan
(http://www.targetscan.org/) and miRanda (http://www.
microrna.org/microrna/home.do), indicates that SMAD4
is theoretically the target gene of miR-224 (Figure 4A).
Therefore, in the current study, we further determined
whether SMAD4 gene was an authentic target gene of
miR-224 in CRC.
We performed a luciferase reporter assay to verify that
miR-224 directly targets SMAD4.Sequences of the 3′
UTR of the SMAD4 mRNA surrounding the two close
miR-224 potential binding sites (site 1 and site 2) contain-
ing the wild-type (WT1).we cloned the regions of 3′UTR
each containing one putative miR-224 binding site into the
psicheck-2 vector and named as WT1 (site1, site2) and
WT2 (site3) (Figure 4A). The reporter constructs harbor-
ing mutation of the miR-224 target sites were generated
similarly (MUT1, MUT2 and MUT3) (Figure 4A). The
luciferase reporter constructs were transfected into HEK
293T cells, along with pre-miR-224 or pre-miR-nc. Lucifer-
ase activites were then measured. The luciferase activity of
WT1 (site1, site2) reporter transfected with pre-miR-224
was significantly decreased compared with control (P<0.01,
Figure 4B), while the luciferase activity of the WT2 (site3)
reporter was not interfered with after transfection with
pre-miR-224 compared with control (P>0.05, Figure 4B).
These data indicate that miR-224 may target SMAD4 gene
through the seeding region of wild type 3′UTR (site1,
site2). However, the luciferase reporter activity was not
inhibited by miR-224 when the seeding sites were mutated.ion in SW480 cells transfected with pre-miR-224 or pre-miR-nc. (B) MTT
AB
Pre-miR-nc                            pre-miR-224
Migration
Invasion
Figure 3 MiR-224 promotes migration and invation of CRC cells in vitro. (A) Representative photographs of migratory cells on the
membrane of transwell chambers in migration and invasion assays (magnification, ×400). (B) The number of migratory/invasive cells was counted
per field. *P<0.05, **P<0.01.
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To further confirm that SMAD4 was the downstream
target of miR-224, we analyzed SMAD4 mRNA and pro-
tein levels in transfected SW480 cells by qRT-PCR and
Western blot. Western blot analysis demonstrated that
high expression of miR-224 dramatically suppressed the
endogenous protein level of SMAD4 (P<0.01, Figure 5B),
while mRNA remained unchanged (P>0.05, Figure 5A).
Thus, SMAD4 is likely to be suppressed by miR-224
through translational inhibition.
Disscussion
It was reported that disease relapse was an important
factor leading to the poor survival of colorectal cancer
patients [17]. At present, poor clinicopathological char-
acteristics and high carcinoembryonic antigen (CEA)
level were known as high risk factors for relapse butwith varying reliability reported [18]. Therefore, effective
biomarkers were wanted to distinguish between patients
with and without high relapse risk followed by appropri-
ate therapy in CRC.
Differential miRNA expression in tumor samples com-
pared to normal samples or between groups of tumor
samples with a favourable and poor clinical outcome
have been used to generate miRNA signatures with po-
tential prognostic and/or predictive value [19,20]. In the
current study, we confirmed that miR-224 expression in
CRC tumor tissues was significantly higher than that in
normal tissues. Furthermore, miR-224 expression levels
were significantly up-regulated in the tissues of CRC pa-
tients with disease relapse compared with those without
disease relapse, and the CRC patients with up-regulated
miR-224 in tumor tissues had a high risk of relapse. Thus,
miR-224 could function as a potential predictive marker
for relapse following radical surgery of colorectal cancer.
Figure 4 SMAD4 is a validated target of miR-224. (A) The wild-type and mutated 3′UTR of SMAD4, with the seed region (site1, site2 and
site3) and base substitutions (bold). (B) Dual luciferase report assays were performed on HEK 293T cells. Each bar represents mean values ± SD
from three independent experiments. **P<0.01.
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miR-224 in regulating CRC cancer progression. Our
results revealed that miR-224 promoted CRC cells
growth, migration and invasion in vitro. To address the
molecular mechanisms involved in miR-224-mediated
changes of biological properties, SMAD4 was selected
for further study because it was predicted to be a target
of miR-224 by bioinformatics analysis. SMAD4 belongs
to the evolutionarily conserved family of SMAD
proteins which are transmitters of signals from the
transforming growth factor-β (TGF-β) superfamilyof cytokines [21]. It is suggested that SMAD4 can
function as a tumor suppressor gene in gastrointestinal
carcinoma [22,23]. Previous study showed that patients
with tumors expressing low SMAD4 levels had signifi-
cantly worse overall and disease-free survival than pa-
tients with high levels in colorectal cancer [24].
Moreover, Loss of SMAD4 expression was found to be
associated with liver metastasis, and reduced SMAD4
expression enhances tumorigenicity in CRC [25]. A re-
cent study also reported that loss of SMAD4 promoted
migration and invasion, and mediated epithelial–
Figure 5 MiR-224 down-regulates SMAD4 protein expression but not mRNA level. (A) The expression of SMAD4 mRNA was analyzed by
qRT-PCR assay. (B) The expression of SMAD4 protein was analyzed by western blot assay. **P<0.01.
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[26,27]. Hence, it is an attractive target for anti-cancer
therapy in colorectal cancer.
Our study suggested that SMAD4 was a possible target
of miR-224. Firstly, the luciferase reporter assaydemonstrated its down-regulation was mediated by the dir-
ect binding of miR-224 to the SMAD4 3′-UTR, because
the alteration of this region abolished this effect. Secondly,
over-expression of miR-224 suppressed SMAD4 protein
levels without any change in SMAD4 mRNA expression.
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224-induced SMAD4 suppression was post-transcriptional.
In addition, SMAD4 has been confirmed as a target gene
of miR-224 in Granulosa Cells [28]. In our study, restor-
ation of miR-224 promoted CRC cell proliferation, migra-
tion and invasion, this could possibly be due to miR-224-
mediated down-regulation of SMAD4 expression.
Cancer stem cells (CSCs) are predicted to be critical
drivers of tumor progression due to CSC characteristics
including self-renewal and pluripotency, drug resistance,
limitless proliferative potential and metastatic capability,
suggesting that targeting CSC characteristics would
likely eliminate CSCs which are the “seeds” of tumor re-
currence and metastasis. Specific miRNAs have been
shown to be involved in CSC regulation in CRC, such as
miR-328 and miR-449b [29,30]. Recently, Fellenberg
et al. showed that the miR-224 functions as an important
regulator of stem cells induction by targeting the apop-
tosis inhibitor, API5 [31]. The generation of CSCs in-
volves a process of mesenchymal-to-epithelial transition
(MET), therefore factors inducing MET or blocking the
EMT by inhibiting TGF-β signaling play an essential role
in cell reprogramming [32]. It is also known that TGF-
β/Smad4 signaling plays a crucial role in the regulation
of EMT as well as cell stemness in CRC [27,33]. We have
discovered a novel target of miR-224 (Smad4), which has
key function in TGF-β signaling, providing the possibil-
ity that miR-224 may mediate CSC by suppressing TGF-
β/Smad4 activity. Thus, our studies might provide a
potential molecular mechanism and crosstalk of CSC
regulation and tumor metastasis.
In summary, the association between increased levels
of miR-224 and disease relapse in CRC patients indi-
cated that miR-224 was a potential biomarker for identi-
fying high-risk CRC patients after radical resection. The
present data showed that miR-224 had oncogenic effects,
including the promotion of CRC cell proliferation, mi-
gration and invasion, at least in part by targeting the
anti-oncogene SMAD4, highlighting the function of
miR-224 in the process of tumor progression.
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